מוגש מטעם רוש פרמצבטיקה (ישראל) בע"מ
References:
1. Breder, V. V. et. Al. , IMbrave150: Exploratory Efficacy and Safety Results of Hepatocellular Carcinoma (HCC) Patients With Main Trunk and/or Contralateral Portal Vein Invasion (Vp4) Treated With Atezolizumab + Bevacizumab vs Sorafenib in a Global Phase III Study ASCO Annual Meeting. June 4–8, 2021. Abstract #4073
2. Cheng A. L. et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus Bevacizumab vs. Sorafenib for unresectable hepatocellular carcinoma. ASCO-GI 2021 and J Hepatol 2022; 76 (4): 862- 873
3.https://www.nccn.org/professionals/physician_gls/pdf/hcc.pdf